Ikena Oncology Inc


Ikena Oncology Inc

  • Price (USD)3.60
  • Today's Change-0.01 / -0.28%
  • Shares traded140.00
  • 1 Year change-40.98%
  • Beta--
Data delayed at least 15 minutes, as of Mar 31 2023 14:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ikena Oncology, Inc. is a targeted oncology company. The Company develops precision medicines tailored to biomarker-defined patient groups with specific unmet needs. The Company approach in each of its programs is to target both cancer-driving targets and mechanisms of resistance to other targeted therapies. The Company’s advanced targeted oncology program, IK-930, is a paralog-selective inhibitor of the transcriptional enhanced associate domain (TEAD). The TEAD transcription factors execute the ultimate step in the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted and chemo therapies. The Company’s first program in the RAS pathways, IK-595, is designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. In addition, it is also developing IK-175, an aryl hydrocarbon receptor (AHR) antagonist in collaboration with Bristol Myers Squibb.

  • Revenue in USD (TTM)15.62m
  • Net income in USD-68.77m
  • Incorporated2016
  • Employees80.00
  • Location
    Ikena Oncology Inc50 Northern Ave.BOSTON 02210United StatesUSA
  • Phone+1 (857) 343-8292
  • Fax+1 (302) 655-5049
  • Websitehttps://www.ikenaoncology.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Paratek Pharmaceuticals Inc160.27m-63.57m121.40m268.00------0.7575-1.18-1.182.97-3.020.89941.672.88598,014.90-35.67-42.62-44.19-48.1685.61---39.66-124.083.22-2.662.99--23.1366.26-7.59---49.69--
Aravive Inc9.14m-76.32m123.88m23.00--11.62--13.56-2.20-2.200.25140.17810.1406--154.86397,260.90-117.47-65.90-169.82-75.91-----835.31-847.43----0.00--22.78-25.57-94.94---69.69--
Carisma Therapeutics Inc40.00m-19.88m124.39m17.00--3.96--3.11-0.0991-0.09910.19910.78020.1861--3.812,352,941.00-9.25-25.47-10.27-27.87-----49.71-236.32----0.00--50.69148.16-5,817.86------
Gracell Biotechnologies Inc (ADR)0.00-88.42m124.54m348.00--0.6219-----1.31-1.310.002.960.00-------32.69---36.37--------------0.1063---100.00---33.89------
Mediwound Ltd26.50m-19.60m125.63m73.00--8.80--4.74-3.85-3.855.321.510.75968.434.77362,958.90-56.19-26.49-83.43-35.2049.6947.32-73.97-42.933.64-0.74670.0719--11.5060.39-44.63---12.39--
Galectin Therapeutics Inc0.00-38.87m128.95m12.00---------0.6545-0.65450.00-0.54180.00----0.00-122.88-84.71-188.84-104.98-----------90.455.22-------26.63------
Invivyd Inc0.00-241.32m129.39m84.00--0.363-----2.23-
ESSA Pharma Inc0.00-32.75m130.07m50.00--0.8028-----0.7433-0.74330.003.670.00----0.00-18.37-27.41-18.72-28.52------------0.00------4.62------
Enzolytics Inc0.00-119.19k130.20m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Ikena Oncology Inc15.62m-68.77m130.89m80.00--0.8906--8.38-1.90-1.900.43164.050.0744----195,225.00-32.73---37.03-------440.29------0.00---49.59---101.57------
Milestone Pharmaceuticals Inc5.00m-58.39m131.32m39.00--1.98--26.26-1.38-1.380.11781.940.0515--5.90128,205.10-60.09-43.13-64.37-45.68-----1,167.76-1,148.11----0.00---66.67---36.25--49.85--
G1 Therapeutics Inc51.30m-147.56m133.28m170.00--1.93--2.60-3.39-3.391.181.330.23210.38156.11301,770.60-66.76-46.91-77.90-51.1692.69---287.63-470.794.59-14.060.5284--62.98--0.5345--11.47--
Puma Biotechnology Inc228.03m2.00k133.86m192.00--6.1615.000.587-0.0043-0.00435.100.46621.029.477.711,187,662.000.0009-24.020.0015-39.2675.8481.330.0009-22.631.672.200.8198---9.9252.46100.01---32.63--
Anixa Biosciences Inc0.00-12.09m135.45m4.00--4.87-----0.3958-0.39580.000.89870.00----0.00-38.54-80.77-39.42-85.60-------3,362.83----0.00---100.00---4.95------
Graphite Bio Inc0.00-101.05m140.17m120.00--0.4736-----1.84-1.840.005.090.00----0.00-27.92---28.93--------------0.00-------42.81------
Data as of Mar 31 2023. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

41.82%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 20223.72m10.27%
BVF Partners LPas of 31 Dec 20222.50m6.90%
Citadel Advisors LLCas of 31 Dec 20222.13m5.87%
CHI Advisors LLCas of 31 Dec 20221.64m4.52%
Verition Fund Management LLCas of 31 Dec 20221.58m4.36%
Invus Public Equities Advisors LLCas of 31 Dec 20221.55m4.27%
The Vanguard Group, Inc.as of 31 Dec 2022975.79k2.69%
Laurion Capital Management LPas of 31 Dec 2022529.00k1.46%
BlackRock Fund Advisorsas of 31 Dec 2022300.79k0.83%
Geode Capital Management LLCas of 31 Dec 2022236.43k0.65%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.